Vidac Pharma to list on Hamburg Stock Exchange
The Israeli clinical stage oncology drug developer has a share subscription facility of up to €20 million from Luxembourg-based GEM.
Source: globes.co.il
Stay updated with breaking news from Becker Photo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Israeli clinical stage oncology drug developer has a share subscription facility of up to €20 million from Luxembourg-based GEM.